Woburn, Mass., July 11 /PRNewswire/ -- VisEn Medical, Inc., a leader in fluorescence in vivo imaging from research through medicine, today announced that John Kleijne will join the Company as Vice President Commercialization and Partnerships, Europe, a new position for the Company. Mr. Kleijne’s role with VisEn further supports and enables the Company’s mission of providing today’s leading research, pharmaceutical and clinical institutions worldwide with the top technologies and solutions in fluorescence molecular imaging. Mr. Kleijne will be based in the Netherlands.
Mr. Kleijne joins VisEn from GE Healthcare, where he led GE’s commercial programs in pre-clinical imaging in Europe. Before working with GE, Mr. Kleijne served as the Chief Commercial Officer for Kreatech Biotechnology in Amsterdam; Director, European Sales for Pyrosequencing in Sweden; and Manager of Business Development at Amersham Pharmacia Biotech. Prior to entering the pharmaceutical industry, he served as a researcher at the National Institute of Public Health and Environmental Protection in the Netherlands. He holds a Masters of Science degree in Molecular Biology from the University of Utrecht.
“John is well established in the European research and molecular imaging community, and he brings a strong level of presence and support to our programs there,” said Jerry Williamson, Chief Commercial Officer for VisEn. “Further, his level of technical expertise and customer-focused industry leadership is exactly what VisEn is bringing to customers as molecular imaging is increasingly integrated into research and drug development worldwide.”
“Continued successful expansion of molecular imaging in research, drug development and healthcare depends on providing the most robust molecular imaging probe and system solutions to top institutions throughout the world,” commented Mr. Kleijne. “It is clear from its scientific heritage, leading technology platforms and market position that VisEn is uniquely poised to deliver this in unparalleled ways. I could not be more pleased by the opportunity to work with VisEn and all of its customers and partners in helping further advance these very exciting markets and opportunities.”
“John’s background, capabilities and experience in the molecular imaging will be major assets in VisEn Medical’s drive to enable and expand European market adoption of our fluorescence molecular imaging platforms,” said Kirtland Poss, President and CEO. “This is an exciting step for VisEn as we continue to partner closely with leading pharmaceutical and academic customers in the space.”
About VisEn Medical, Inc.
VisEn Medical, Inc. was founded in 2000 based on fluorescence molecular imaging technologies initially developed by industry-leading researchers and clinicians at the Massachusetts General Hospital and Harvard Medical School. VisEn is developing the industry’s highest performing fluorescence molecular imaging technology platforms, from research through medicine. The Company also works directly with partners to design ranges of tailored probes and applications that are targeted to their specific research areas. Privately- held VisEn is headquartered in Woburn, Massachusetts and has been financed by leading venture firms including Flagship Ventures and The Bollard Group. For further information please visit www.visenmedical.com.
Contact Information for John Kleijne: John Kleijne VP Commercialization and Partnerships Europe VisEn Medical, BV. Tel: + 31 555 762 724 Mob: + 31 622 998 680 e-mail: jkleijne@visenmedical.com
VisEn Medical, Inc.
CONTACT: Kirtland G. Poss of VisEn Medical, Inc., +1-781-932-6875, X 301
Web site: http://www.visenmedical.com/
